Sugi Predict

Sugi Predict / Compounds / SCHEMBL24685136

SCHEMBL24685136

SCHEMBL24685136

C[C@H]1CN(C(=O)OC(C)(C)C)[C@@H](C)CN1C(=O)Cl

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.50
▸ NR1H2 P55055 1/20 0.41
▸ CHRM2 P08172 1/20 0.41
▸ CHRM1 P11229 1/20 0.41
▸ CHRM3 P20309 1/20 0.41
▸ GPR119 Q8TDV5 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.38
▸ MAPT P10636 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ SETD7 Q8WTS6 1/20 0.37
▸ HSD11B1 P28845 1/20 0.36
▸ MAP4K4 O95819 1/20 0.36
▸ USP2 O75604 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29942781 1.00 TSHR (0.50) TSHRNR1H2CHRM2CHRM1CHRM3
SCHEMBL30591044 1.00 TSHR (0.50) TSHRNR1H2CHRM2CHRM1CHRM3
SCHEMBL29942260 1.00 TSHR (0.50) TSHRNR1H2CHRM2CHRM1CHRM3
SCHEMBL24684727 1.00 TSHR (0.50) TSHRNR1H2CHRM2CHRM1CHRM3
SCHEMBL527701 0.89 TSHR (0.56) TSHRNR1H2CHRM2CHRM1CHRM3
SCHEMBL344752 0.89 TSHR (0.56) TSHRNR1H2CHRM2CHRM1CHRM3
SCHEMBL271429 0.89 TSHR (0.56) TSHRNR1H2CHRM2CHRM1CHRM3
SCHEMBL14915954 0.84 TSHR (0.48) TSHRNR1H2CHRM2CHRM1CHRM3
SCHEMBL14915953 0.84 TSHR (0.48) TSHRNR1H2CHRM2CHRM1CHRM3
SCHEMBL12021385 0.82 TSHR (0.50) TSHRNR1H2CHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250236608-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2025-07-24 — — US disclosed
EP-4504719-A1 EGFR INHIBITORS Blueprint Medicines Corporation (US) 2025-02-12 — — EP disclosed
CN-119325471-A EGFR inhibitors 缆图药品公司 2025-01-17 — — CN disclosed
US-11834458-B2 Anti-cancer nuclear hormone receptor-targeting compounds NUVATION BIO INC. (US) 2023-12-05 — — US disclosed
US-11834458-B2 Anti-cancer nuclear hormone receptor-targeting compounds NUVATION BIO INC. (US) 2023-12-05 — — US disclosed
WO-2023196283-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2023-10-12 — — WO disclosed
WO-2022204184-A1 ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS NUVATION BIO INC. (US) 2022-09-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11834458-B2 Anti-cancer nuclear hormone receptor-targeting compounds NCOA1, NCOR1, NCOA3 TSHR 115/4885NR1H2 13/4885CHRM2 4655/4885
US-20250236608-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 TSHR 976/4885NR1H2 3270/4885CHRM2 4880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.